These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 17117683)

  • 21. Filling the pipeline for neglected diseases: creation of a medicinal chemistry-centric international drug discovery institute [iDDi].
    Kozikowski AP; Reitz AB
    Drug Discov Today; 2008 Feb; 13(3-4):97-8. PubMed ID: 18275906
    [No Abstract]   [Full Text] [Related]  

  • 22. What's fueling the biotech engine-2007.
    Aggarwal S
    Nat Biotechnol; 2008 Nov; 26(11):1227-33. PubMed ID: 18997759
    [No Abstract]   [Full Text] [Related]  

  • 23. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 25. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
    Fitzgerald GA
    Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of microwave synthesis on drug discovery.
    Kappe CO; Dallinger D
    Nat Rev Drug Discov; 2006 Jan; 5(1):51-63. PubMed ID: 16374514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outsourcing lead optimisation--the quiet revolution.
    Clark DE; Newton CG
    Drug Discov Today; 2004 Jun; 9(11):492-500. PubMed ID: 15149625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomics and drug discovery.
    Van Osta P; Ver Donck K; Bols L; Geysen J
    Cytometry A; 2006 Mar; 69(3):117-8. PubMed ID: 16496374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
    Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fostering culture and optimizing organizational structure for implementing model-based drug development.
    Zhang L; Allerheiligen SR; Lalonde RL; Stanski DR; Pfister M
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):146S-150S. PubMed ID: 20881228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometry analysis of new chemical entities for pharmaceutical discovery.
    Fang AS; Miao X; Tidswell PW; Towle MH; Goetzinger WK; Kyranos JN
    Mass Spectrom Rev; 2008; 27(1):20-34. PubMed ID: 18033735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.
    Shumoogam J; Al-Shamahi A
    IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
    Rai AK; Reichman JH; Uhlir PF; Crossman C
    Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
    [No Abstract]   [Full Text] [Related]  

  • 37. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural product hybrids as new leads for drug discovery.
    Tietze LF; Bell HP; Chandrasekhar S
    Angew Chem Int Ed Engl; 2003 Sep; 42(34):3996-4028. PubMed ID: 12973759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemistry strategies in early drug discovery: an overview of recent trends.
    Colombo M; Peretto I
    Drug Discov Today; 2008 Aug; 13(15-16):677-84. PubMed ID: 18675762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
    Wetherington JD; Pfister M; Banfield C; Stone JA; Krishna R; Allerheiligen S; Grasela DM
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):31S-46S. PubMed ID: 20881215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.